Published

Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychopharmacology (Oxford, England)
Date: 2025-09-01
Source: PubMed
DOI: 10.1177/02698811251353250
PubMed: 40643096

Authors

Swieczkowski D Kwaśny A Ciurkowska P Pruc M Szarpak L Cubała WJ

Watch author

Derived topics and classifications

psilocybin psilocin Aging Clinical Trial Review Article Healthy Volunteers Older Adults Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 4 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization2026-05-13 Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols2026-04-01 Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis2026-04-01 Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics.2025-09-01

Related papers

Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot StudyClinicalTrials.gov · 2026-03-18 Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.Expert opinion on drug safety · 2022-06-01 Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling.Therapeutic advances in drug safety · 2026-01-01 Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin CompoundsACS Omega · 2025-09-30 Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.Drug safety · 2025-05-01 Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents.Expert opinion on drug safety · 2023-01-01 [DNA and chemical analyses of commercial fly agaric-related products].Shokuhin eiseigaku zasshi. Journal of the Food Hygienic Society of Japan · 2005-04-01 [Discrimination of psychoactive fungi (commonly called "magic mushrooms") based on the DNA sequence of the internal transcribed spacer region].Shokuhin eiseigaku zasshi. Journal of the Food Hygienic Society of Japan · 2003-02-01